Vast Genome Trial Aims to Redefine Newborn Health Screening

For decades, newborn screening has been a public health success, but it currently checks for a maximum of 80 conditions. Meanwhile, effective treatments are available for up to 2,000 severe childhood genetic diseases, creating a vast diagnostic gap.

A new international trial, BeginNGS, aims to close this gap using genome sequencing-based newborn screening (gNBS), a method that can identify almost all such genetic conditions from a bloodspot. The multicentre study will enrol a minimum of 10,000 newborns from diverse populations to compare the clinical utility of gNBS against the standard method.

Researchers hypothesise that BeginNGS will identify a greater number of treatable conditions, improving health outcomes. The trial uses an innovative 'adaptive' design, allowing its organisation to be refined as data accumulates. This makes the research more efficient and equitable, ensuring it can better serve under-represented groups and even assess ultra-rare diseases.